IL-21 antibody (PE)

Catalog No. ABIN2663780

The PE-conjugated Mouse Monoclonal anti-IL-21 antibody (Clone 4BG1) (ABIN2663780) specifically detects IL-21 in BCA. The antibody is reactive with Human samples.

Quick Overview for IL-21 antibody (PE) (ABIN2663780)

Target: IL-21 (IL21) (Interleukin 21 (IL21))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This IL-21 antibody is conjugated to PE

Application: Biochemical Assay (BCA)

Clone: 4BG1

Product Details anti-IL-21 Antibody (PE)

Purification: The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.

Isotype: IgG2b kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Protect from prolonged exposure to light. Do not freeze.

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C.

Target Details for IL-21

Target: IL-21 (IL21) (Interleukin 21 (IL21))

Alternative Name: IL-21

Background: Interleukin 21 (IL-21) is a potent immunomodulatory cytokine mainly produced by NKT and CD4+ T-cells, particularly the inflammatory Th17 subset and has pleiotropic effects on both innate and adaptive immune responses. These actions include positive effects such as enhancing proliferation of NK cells and cytotoxic T cells, and inhibitory effects on the antigen-presenting function of dendritic cells. It can also be proapoptotic for B cells and NK cells. Recent studies have shown that IL-21 is also an autocrine cytokine that potently induces Th17 differentiation and suppresses Foxp3 expression, and serves as a target for treating inflammatory diseases.

Pathways: JAK-STAT Signaling, Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Production of Molecular Mediator of Immune Response